<DOC>
	<DOCNO>NCT00055757</DOCNO>
	<brief_summary>Phase II trial study effectiveness combine tipifarnib gemcitabine cisplatin treat patient stage III stage IV non-small cell lung cancer . Drugs use chemotherapy gemcitabine cisplatin use different way stop tumor cell divide stop grow die . Tipifarnib may stop growth tumor cell block enzymes necessary tumor cell growth . Combining tipifarnib combination chemotherapy may kill tumor cell .</brief_summary>
	<brief_title>Tipifarnib , Gemcitabine , Cisplatin Treating Patients With Stage III Stage IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To describe response rate non-small cell lung cancer ( NSCLC ) patient receive combination therapy R115777 , gemcitabine , cisplatin . SECONDARY OBJECTIVES : I . To estimate time event efficacy variable include : time progressive disease , time treatment failure , time death cause . II . To estimate duration response respond patient . III . To characterize toxicity R115777 , gemcitabine , cisplatin patient population . TERTIARY OBJECTIVES : I . To evaluate association polymorphism expression candidate gene clinical endpoint toxicity R115777 , gemcitabine , cisplatin . OUTLINE : This multicenter study . Patients receive oral tipifarnib twice daily day 1-14 , gemcitabine IV 30 minute day 1 8 , cisplatin IV 2 hour day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients least stable disease may continue receive oral tipifarnib alone twice daily day 1-14 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Patients follow every 6 month 2 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Tipifarnib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm NSCLC one follow classification : Stage IIIB pleural effusion Stage IIIB candidate combine modality treatment radiation therapy chemotherapy Stage IV Measurable disease , define least one lesion whose long diameter accurately measure &gt; = 2.0 cm Absolute neutrophil count ( ANC ) &gt; = 1500/mm^3 PLT &gt; = 100,000 Hgb &gt; 10.0 g/dL Direct bilirubin = &lt; 1.5 x UNL Alkaline phosphatase = &lt; 5 x UNL AST = &lt; 3 x UNL Creatinine = &lt; 1.5 x UNL ECOG Performance Status ( PS ) 0 1 Capable understanding investigational nature , potential risk benefit study able provide valid informed consent Any follow regimen may harmful develop fetus nursing child : Pregnant woman Breastfeeding woman Men woman childbearing potential sexual partner unwilling employ adequate contraception ( condom , diaphragm , birth control pill , injection , intrauterine device [ IUD ] , surgical sterilization , subcutaneous implant , abstinence , etc . ) Any follow prior therapy : Prior chemotherapy NSCLC ( exception : therapy use radiosensitizer lowdose weekly cisplatin carbo/taxol XRT ) Prior radiation &gt; 25 % bone marrow Prior immunotherapy , biologic gene therapy New York Heart Association classification III IV CNS metastases Uncontrolled infection Any severe , underlie disease , judgment investigator , inappropriate entry study Prior malignancy , except adequately treat basal cell squamous cell skin cancer , adequately treat noninvasive carcinoma , cancer patient diseasefree least five year Preexisting peripheral neuropathy ( motor sensory ) &gt; grade 1 per NCI Common Toxicity Criteria ( CTC ) Known peripheral vascular disease history deep vein thrombosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>